Actinium Pharmaceuticals Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $90K+11.1% YoYTTM through 30 Jun 2026
Net Income $11.3MTTM through 30 Jun 2026
Free Cash Flow -$22.8MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Operating Margin | -39,362.2% |
| Net Margin | -37,652.2% |
Returns
-432.6%ROE
-65.5%ROA
-355.7%ROIC
Balance Sheet Health
Debt / Equity0.22x
Current Ratio6.20x
Net Debt-$46.3Mnet cash position
Cash & Equivalents$36.5M
Quality Metrics
Altman Z-Score-9.63
Piotroski F-Score2 / 9
FCF Margin-25,292.2%
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $90K
Diluted EPS$0.35TTMFY2025: $-1.09
Dividend
No dividend
Capital Allocation
Capex Intensity111.1%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Targeted Radiotherapies | $90K | +11.1% | View detailsFocus remains on clinical development, establishing cyclotron manufacturing infrastructure, and seeking strategic partnerships for commercialization. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.